Over the past year, approximately 12 million people have lost coverage for the obesity drug Zepbound. This significant loss reflects a broader trend affecting access to essential healthcare treatments.
The same number of individuals have also lost coverage for Wegovy, another medication aimed at treating obesity. These changes have raised alarms about the implications for patient care and treatment options.
An analysis by GoodRx, a drug discount website, sheds light on these coverage restrictions, highlighting the challenges many face in accessing necessary medications for obesity.